Cargando…
Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models
SIMPLE SUMMARY: Grade 4 gliomas and glioblastomas are the most common brain tumors, accounting for 50% of primary brain tumors, and the most aggressive, with a median 5-year patient survival of less than 10%. There is no therapy to date that can sustainably prolong the life of patients. In this work...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527257/ https://www.ncbi.nlm.nih.gov/pubmed/37760448 http://dx.doi.org/10.3390/cancers15184478 |